[J01EC01, sulfamethoxazole, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Sulfamethoxazole.]
[S01AB02, sulfisoxazole, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Sulfisoxazole.]
[N05AL01, sulpiride, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Sulpiride.]
[L02BA01, tamoxifen, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Tamoxifen.]
[R03CC03, terbutaline, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Terbutaline.]
[N07XX06, tetrabenazine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Tetrabenazine.]
[N05AE05, lurasidone, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Lurasidone.]
[N04BC07, apomorphine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Apomorphine.]
[L01XX41, eribulin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Eribulin.]
[N05AC02, thioridazine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Thiothixene.]
[S01ED01, timolol, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Timolol.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Oxytocin.]
[A03AA05, trimebutine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Trimebutine.]
[R06AD01, trimeprazine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Alimemazine.]
[N03AC02, trimethadione, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Trimethadione.]
[N06AA06, trimipramine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Trimipramine.]
[R06AX07, triprolidine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Triprolidine.]
[L01EX04, vandetanib, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Vandetanib.]
[J05AG05, rilpivirine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Rilpivirine.]
[N03AX21, ezogabine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ezogabine.]
[R03AC18, indacaterol, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Indacaterol.]
[N05AF05, zuclopenthixol, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Zuclopenthixol.]
[L01EC01, vemurafenib, The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Oxytocin.]
[L01ED01, crizotinib, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Crizotinib.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ibandronate.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ziprasidone.]
[G04BD07, tolterodine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Tolterodine.]
[J02AC03, voriconazole, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Voriconazole.]
[S01FA01, atropine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Atropine.]
[G04BD12, mirabegron, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Mirabegron.]
[C01CA18, octopamine, The risk or severity of hypertension can be increased when Octopamine is combined with Oxytocin.]
[J05AE04, nelfinavir, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Nelfinavir.]
[H01CB05, pasireotide, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Pasireotide.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Bedaquiline.]
[C04AX11, bencyclane, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Bencyclane.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Gemifloxacin.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Moxifloxacin.]
[N02CC02, naratriptan, The risk or severity of hypertension can be increased when Naratriptan is combined with Oxytocin.]
[N04AC01, benztropine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Benzatropine.]
[L01EC02, dabrafenib, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dabrafenib.]
[C08EA02, bepridil, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Bepridil.]
[L01ED02, ceritinib, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ceritinib.]
[A03BA03, hyoscyamine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Hyoscyamine.]
[R03AC19, olodaterol, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Olodaterol.]
[A16AX10, eliglustat, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Eliglustat.]
[N06AX11, mirtazapine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Mirtazapine.]
[L01EX08, lenvatinib, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Lenvatinib.]
[L01XH03, panobinostat, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Panobinostat.]
[C01EB17, ivabradine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ivabradine.]
[B02BC05, adrenalone, The risk or severity of hypertension can be increased when Adrenalone is combined with Oxytocin.]
[G04CA01, alfuzosin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Alfuzosin.]
[R06AB01, brompheniramine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dexbrompheniramine.]
[C07AA19, bupranolol, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Bupranolol.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Buserelin.]
[L01XX27, arsenic trioxide, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Arsenic trioxide.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Artemether.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Azatadine.]
[S01AA26, azithromycin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Azithromycin.]
[L01EF02, ribociclib, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ribociclib.]
[N07XX16, deutetrabenazine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Deutetrabenazine.]
[N02BF02, pregabalin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Pregabalin.]
[J01MA23, delafloxacin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Delafloxacin.]
[L01XH01, vorinostat, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Vorinostat.]
[J05AG03, efavirenz, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Efavirenz.]
[N06AA15, butriptyline, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Butriptyline.]
[C01AA02, acetyldigoxins, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Acetyldigoxin.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Acrivastine.]
[C01CX09, angiotensin II, The risk or severity of hypertension can be increased when Angiotensin II is combined with Oxytocin.]
[V04CD06, macimorelin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Macimorelin.]
[R06AA08, carbinoxamine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Carbinoxamine.]
[L01EC03, encorafenib, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Encorafenib.]
[C07AB08, celiprolol, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Celiprolol.]
[L01XX62, ivosidenib, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ivosidenib.]
[S01GX12, cetirizine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Cetirizine.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Inotersen.]
[L01EX13, gilteritinib, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Gilteritinib.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Amifampridine.]
[C01BG07, cifenline, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Cibenzoline.]
[B01AC23, cilostazol, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Cilostazol.]
[P02BX04, triclabendazole, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Triclabendazole.]
[J01FA09, clarithromycin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Clarithromycin.]
[C03BX03, cicletanine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Cicletanine.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Entrectinib.]
[N07XX11, pitolisant, Oxytocin may increase the QTc-prolonging activities of Pitolisant.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Oxytocin.]
[R06AB06, dexbrompheniramine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dexbrompheniramine.]
[R06AB02, dexchlorpheniramine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dexchlorpheniramine.]
[S01AE06, gatifloxacin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Gatifloxacin.]
[C01BD07, dronedarone, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dronedarone.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Chlorcyclizine.]
[R06AX22, ebastine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ebastine.]
[J05AX29, fostemsavir, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Fostemsavir.]
[P01BA01, chloroquine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Chloroquine.]
[R06AB04, chlorpheniramine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Chlorpromazine.]
[N05AF03, chlorprothixene, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Chlorprothixene.]
[B06AC06, berotralstat, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Berotralstat.]
[L02BX04, relugolix, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Relugolix.]
[N03AX10, felbamate, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Felbamate.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Flumequine.]
[R03CC15, formoterol, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Formoterol.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Oxytocin.]
[N07CA02, cinnarizine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Cinnarizine.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Cinoxacin.]
[S03AA07, ciprofloxacin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ciprofloxacin.]
[N06AB04, citalopram, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Citalopram.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Oxytocin is combined with Fexinidazole.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Mobocertinib.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Clemastine.]
[J04BA01, clofazimine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Clofazimine.]
[L01EJ03, pacritinib, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Pacritinib.]
[N06AA04, clomipramine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Clomipramine.]
[A04AA01, ondansetron, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ondansetron.]
[A04AA02, granisetron, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Granisetron.]
[N05AH02, clozapine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Clozapine.]
[S02DA02, cocaine, The risk or severity of hypertension can be increased when Cocaine is combined with Oxytocin.]
[N01AB07, desflurane, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Desflurane.]
[J01FA15, telithromycin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Telithromycin.]
[R06AX27, desloratadine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Desloratadine.]
[J02AC02, itraconazole, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Itraconazole.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Emedastine.]
[L01EA01, imatinib, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Imatinib.]
[J02AC04, posaconazole, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Posaconazole.]
[C08CA09, lacidipine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Lacidipine.]
[N03AX09, lamotrigine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Lamotrigine.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Levocabastine.]
[N07BC04, lofexidine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Lofexidine.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Lomefloxacin.]
[R06AD07, mequitazine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Mequitazine.]
[C01EB10, adenosine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Adenosine.]
[R06AE03, cyclizine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Cyclizine.]
[N05AD03, metylperon, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Melperone.]
[R06AX02, cyproheptadine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Cyproheptadine.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Moexipril.]
[G04BE09, vardenafil, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Vardenafil.]
[N06AB10, escitalopram, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Escitalopram.]
[G04BD08, solifenacin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Solifenacin.]
[N06AA01, desipramine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Desipramine.]
[L01XA03, oxaliplatin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Oxaliplatin.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Foscarnet.]
[A03AX04, pinaverium, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Pinaverium.]
[L01EB02, erlotinib, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Erlotinib.]
[C08CA03, isradipine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Isradipine.]
[C01AA04, digitoxin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Digitoxin.]
[C01AA05, digoxin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Digoxin.]
[N02CA01, dihydroergotamine, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Oxytocin.]
[J05AE08, atazanavir, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Atazanavir.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Treprostinil.]
[C08DB01, diltiazem, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Diltiazem.]
[R06AA11, dimenhydrinate, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dimenhydrinate.]
[G02AD02, dinoprostone, The risk or severity of adverse effects can be increased when Dinoprostone is combined with Oxytocin.]
[R06AA02, diphenhydramine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Diphenhydramine.]
[A03FA02, cisapride, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Cisapride.]
[C01BA03, disopyramide, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Disopyramide.]
[P03AA04, disulfiram, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Disulfiram.]
[N05AX08, risperidone, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Risperidone.]
[R06AE09, levocetirizine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Levocetirizine.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Rosoxacin.]
[L01EX01, sunitinib, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Sunitinib.]
[L01XG01, bortezomib, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Bortezomib.]
[C01EB18, ranolazine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ranolazine.]
[R03AC12, salmeterol, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Salmeterol.]
[A03FA03, domperidone, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Domperidone.]
[N06AA16, dothiepin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dosulepin.]
[N06AA12, doxepin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Doxepin.]
[R06AA09, doxylamine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Doxylamine.]
[N01AB08, sevoflurane, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Sevoflurane.]
[N05AD08, droperidol, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Droperidol.]
[N05AL02, sultopride, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Sultopride.]
[N02CC01, sumatriptan, The risk or severity of hypertension can be increased when Sumatriptan is combined with Oxytocin.]
[C07AB13, talinolol, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Talinolol.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Temafloxacin.]
[G04BD05, terodiline, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Terodiline.]
[S01GA02, tetrahydrozoline, The risk or severity of hypertension can be increased when Tetryzoline is combined with Oxytocin.]
[N06BA09, atomoxetine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Atomoxetine.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Toremifene.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Triptorelin.]
[J01MA04, enoxacin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Enoxacin.]
[S01FB02, ephedrine, The risk or severity of hypertension can be increased when Oxytocin is combined with Ephedrine.]
[S01GX10, epinastine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Epinastine.]
[S01GA03, xylometazoline, The risk or severity of hypertension can be increased when Xylometazoline is combined with Oxytocin.]
[S01EA01, epinephrine, The risk or severity of hypertension can be increased when Epinephrine is combined with Oxytocin.]
[N03AX15, zonisamide, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Zonisamide.]
[C01BG01, moricizine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Moricizine.]
[N02CA02, ergotamine, The risk or severity of hypertension can be increased when Ergotamine is combined with Oxytocin.]
[N03AG01, valproic acid, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Valproic acid.]
[S01AA17, erythromycin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Erythromycin.]
[D07AC21, halobetasol, The risk or severity of hypertension can be increased when Ulobetasol is combined with Oxytocin.]
[C01BD05, ibutilide, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ibutilide.]
[N03AD01, ethosuximide, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ethosuximide.]
[C01CA01, etilefrine, The risk or severity of hypertension can be increased when Etilefrine is combined with Oxytocin.]
[C01BA05, ajmaline, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ajmaline.]
[L04AD02, tacrolimus, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Tacrolimus.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Fleroxacin.]
[R06AX11, astemizole, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Astemizole.]
[R06AX12, terfenadine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Terfenadine.]
[G02AD06, misoprostol, The risk or severity of adverse effects can be increased when Misoprostol is combined with Oxytocin.]
[C01BC08, encainide, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Encainide.]
[L02AE02, leuprolide, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Leuprolide.]
[A02BA03, famotidine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Famotidine.]
[C08CA02, felodipine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Felodipine.]
[C08EA01, fendiline, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Fendiline.]
[R03CC02, albuterol, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Salbutamol.]
[C01BC04, flecainide, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Flecainide.]
[J02AC01, fluconazole, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Fluconazole.]
[L01BC02, fluorouracil, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Fluorouracil.]
[N06AB03, fluoxetine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Oxytocin.]
[N05AF01, flupenthixol, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Flupentixol.]
[N05AG01, fluspirilene, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Fluspirilene.]
[N05AL05, amisulpride, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Amisulpride.]
[N06DA04, galantamine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Galantamine.]
[C08DA02, gallopamil, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Gallopamil.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Telavancin.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Degarelix.]
[L01EA02, dasatinib, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dasatinib.]
[N03AD03, methsuximide, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Methsuximide.]
[L01EH01, lapatinib, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Lapatinib.]
[C01BD04, dofetilide, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dofetilide.]
[L01EX02, sorafenib, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Sorafenib.]
[C07AB09, esmolol, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Esmolol.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Goserelin.]
[P01BX01, halofantrine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Haloperidol.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Histrelin.]
[N05AH04, quetiapine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Quetiapine.]
[C09CA01, losartan, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Losartan.]
[C08CA10, nilvadipine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Nilvadipine.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Oxatomide.]
[C03AA03, hydrochlorothiazide, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Hydrochlorothiazide.]
[P01BA02, hydroxychloroquine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Hydroxychloroquine.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Hydroxyzine.]
[N06AA02, imipramine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Imipramine.]
[H01BA04, terlipressin, The risk or severity of hypertension can be increased when Terlipressin is combined with Oxytocin.]
[M03BX02, tizanidine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Tizanidine.]
[C03BA11, indapamide, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Indapamide.]
[R06AE01, buclizine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Buclizine.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Anagrelide.]
[N01AB06, isoflurane, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Isoflurane.]
[J02AB02, ketoconazole, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ketoconazole.]
[N05AH03, olanzapine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Olanzapine.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Mizolastine.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Nalidixic acid.]
[N04BB01, amantadine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Amantadine.]
[C08EX01, lidoflazine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Lidoflazine.]
[A07DA03, loperamide, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Loperamide.]
[H01BA03, lypressin, The risk or severity of hypertension can be increased when Lypressin is combined with Oxytocin.]
[L01EA03, nilotinib, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Nilotinib.]
[N06AA21, maprotiline, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Maprotiline.]
[P01BC02, mefloquine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Mefloquine.]
[C01CA11, mephentermine, The risk or severity of hypertension can be increased when Mephentermine is combined with Oxytocin.]
[N05AC03, mesoridazine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Mesoridazine.]
[N05AX13, paliperidone, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Paliperidone.]
[C01CA09, metaraminol, The risk or severity of hypertension can be increased when Metaraminol is combined with Oxytocin.]
[A04AA04, dolasetron, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dolasetron.]
[N07BC02, methadone, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Methadone.]
[N05AA02, methotrimeprazine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Methotrimeprazine.]
[C01CA10, methoxamine, The risk or severity of hypertension can be increased when Methoxamine is combined with Oxytocin.]
[N02CA04, methysergide, The risk or severity of hypertension can be increased when Methysergide is combined with Oxytocin.]
[A03FA01, metoclopramide, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Metoclopramide.]
[P01AB01, metronidazole, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Metronidazole.]
[C01CA17, midodrine, The risk or severity of hypertension can be increased when Midodrine is combined with Oxytocin.]
[G03XB01, mifepristone, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Mifepristone.]
[C01BD01, amiodarone, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Amiodarone.]
[N06AA09, amitriptyline, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Amitriptyline.]
[L01EX03, pazopanib, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Pazopanib.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Amodiaquine.]
[N06AA17, amoxapine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Amoxapine.]
[S01GA01, naphazoline, The risk or severity of hypertension can be increased when Naphazoline is combined with Oxytocin.]
[C01CX08, levosimendan, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Levosimendan.]
[N05AX14, iloperidone, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Iloperidone.]
[C08CA04, nicardipine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Nicardipine.]
[C08CA05, nifedipine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Nifedipine.]
[C08CA06, nimodipine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Nimodipine.]
[C08CA08, nitrendipine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Nitrendipine.]
[C01CA03, norepinephrine, The risk or severity of hypertension can be increased when Norepinephrine is combined with Oxytocin.]
[S01AE02, norfloxacin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Norfloxacin.]
[N06AA10, nortriptyline, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Nortriptyline.]
[H01CB02, octreotide, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Oxytocin.]
[S02AA16, ofloxacin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ofloxacin.]
[H01BA05, ornipressin, The risk or severity of hypertension can be increased when Ornipressin is combined with Oxytocin.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Oxolinic acid.]
[S01GA04, oxymetazoline, The risk or severity of hypertension can be increased when Oxymetazoline is combined with Oxytocin.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Pipemidic acid.]
[N05AH05, asenapine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Asenapine.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Papaverine.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Pefloxacin.]
[N05AG03, penfluridol, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Penfluridol.]
[C08EX02, perhexiline, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Perhexiline.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Pheniramine.]
[S01GA05, phenylephrine, The risk or severity of hypertension can be increased when Oxytocin is combined with Phenylephrine.]
[R01BA01, phenylpropanolamine, The risk or severity of hypertension can be increased when Phenylpropanolamine is combined with Oxytocin.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Levofloxacin.]
[C08CX01, mibefradil, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Mibefradil.]
[N05AG02, pimozide, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Pimozide.]
[J05AE01, saquinavir, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Saquinavir.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Grepafloxacin.]
[J05AE03, ritonavir, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ritonavir.]
[C01BA08, prajmaline, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Prajmaline.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Antazoline.]
[C01DX02, prenylamine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Prenylamine.]
[P01BA03, primaquine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Primaquine.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Probucol.]
[C01BA02, procainamide, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Procainamide.]
[N05AB04, prochlorperazine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Prochlorperazine.]
[N05AA03, promazine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Promazine.]
[R06AD02, promethazine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Promethazine.]
[C01BC03, propafenone, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Propafenone.]
[L01XH02, romidepsin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Romidepsin.]
[N01AX10, propofol, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Propofol.]
[N06AA11, protriptyline, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Protriptyline.]
[R01BA02, pseudoephedrine, The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Oxytocin.]
[N05AX12, aripiprazole, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Aripiprazole.]
[R06AC01, pyrilamine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Mepyramine.]
[C01BA01, quinidine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Quinidine.]
[P01BC01, quinine, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Quinine.]
[J01FA06, roxithromycin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Roxithromycin.]
[C07AA07, sotalol, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Sotalol.]
